Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Free Report) was the target of a large decline in short interest in June. As of June 15th, there was short interest totaling 63,530 shares, a decline of 46.6% from the May 31st total of 119,012 shares. Based on an average daily trading volume, of 126,040 shares, the short-interest ratio is presently 0.5 days. Approximately 0.6% of the shares of the stock are sold short.
Analysts Set New Price Targets
Several analysts have issued reports on the stock. HC Wainwright reduced their price target on shares of Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Oppenheimer began coverage on Aprea Therapeutics in a report on Thursday, May 7th. They issued an “outperform” rating and a $5.00 price target for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Monday, April 20th. Finally, Wedbush cut their target price on shares of Aprea Therapeutics from $7.00 to $6.00 and set an “outperform” rating for the company in a research note on Thursday, May 14th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Aprea Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $4.07.
Get Our Latest Stock Report on Aprea Therapeutics
Institutional Trading of Aprea Therapeutics
Aprea Therapeutics Price Performance
APRE traded down $0.00 during trading on Wednesday, hitting $0.80. The company’s stock had a trading volume of 6,466 shares, compared to its average volume of 1,244,467. Aprea Therapeutics has a twelve month low of $0.55 and a twelve month high of $2.22. The stock has a market cap of $9.88 million, a PE ratio of -0.52 and a beta of 1.51. The firm’s 50 day moving average price is $0.84 and its 200-day moving average price is $0.82.
Aprea Therapeutics (NASDAQ:APRE – Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. Aprea Therapeutics had a negative return on equity of 61.03% and a negative net margin of 4,405.59%. Equities analysts anticipate that Aprea Therapeutics will post -0.84 earnings per share for the current year.
About Aprea Therapeutics
Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.
Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.
Featured Articles
- Five stocks we like better than Aprea Therapeutics
- Ouster Is Breaking Out as a Physical AI Leader: Here’s What’s Driving the Move
- Meta’s WhatsApp Shakeup Could Put India at the Center of Its Next Growth Push
- 3 Big Banks Plan Double Digit Dividend Increases After Passing Fed Stress Test
- 3 ETFs Offering Exposure to Latin America’s Stock Market Rally
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
